Cyclacel Pharmaceuti (CYCC) 5.95 $CYCC
Cyclacel Pharma (CYCC) Stock Skyrockets 50% on Positive Phase 1 Data
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 3:13PM CDT
On Monday, shares of Cyclacel Pharmaceuticals (CYCC) are skyrocketing, up over 50% after the company reported positive Phase 1 data for one of its lead drug candidates.
CYCC: 5.95 (-0.14)
Top Trending Stocks to Consider On Monday, June 6
ACCESSWIRE - Mon Jun 06, 1:01PM CDT
MIAMI, FL / ACCESSWIRE / June 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. Helios and Matheson Analytics Inc. (HMNY), LifeClips Inc. (LCLP), Cyclacel Pharmaceuticals, Inc. (CYCC) and Vascular Biogenics Ltd. (VBLT) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
CYCC: 5.95 (-0.14), VBLT: 4.90 (+0.10), HMNY: 9.29 (-1.81)
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
GlobeNewswire - Mon Jun 06, 9:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA damage response program evaluating a combination regimen of two Cyclacel product candidates, seliciclib, a cyclin dependent kinase (CDK) inhibitor, and sapacitabine, a nucleoside analogue. The regimen was orally-administered as sequential (Part 1) or concomitant (Part 2) treatment to 67 heavily-pretreated patients with advanced solid tumors. Antitumor activity was demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with a 35.6% disease control rate (1 CR, 5 PR and 10 SD). Treatment durations in responders ranged between 16 and over 240 weeks. No CR or PR was observed in BRCA negative patients. Data were presented at an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Reverse Stock Split
GlobeNewswire - Fri May 27, 4:00PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that effective at 5:00 p.m., Eastern Time, on May 27, 2016 (the "Effective Time" , the Company will effect a one-for-twelve reverse stock split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company's Board of Directors, was approved by its stockholders at the Annual Meeting of Stockholders held on May 26, 2016. The Company's common stock will open for trading on The NASDAQ Capital Market on May 31, 2016 on a post-split basis.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid tumors at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2016.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce first quarter 2016 financial results on Wednesday, May 11, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
GlobeNewswire - Mon Apr 18, 8:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent. The data show that CYC065 can induce cell death and combined beneficially with anti-cancer drugs from the Bcl-2 and BET inhibitor classes, in in vitro models of B-cell lymphoma, including double-hit lymphomas. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16 - 20, 2016, in New Orleans.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Receipt of Nasdaq Extension
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company" a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company received a written ruling from the NASDAQ Hearings Panel (the "Panel" stating that the Panel has granted the Company's request to remain listed on The NASDAQ Capital Market.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
GlobeNewswire - Fri Feb 05, 3:20PM CST
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company" today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff" of The NASDAQ Stock Market LLC ("NASDAQ" indicating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(a)(1), by the end of the previously granted compliance period that expired on February 2, 2016. As a result, the Staff indicated that the Company would be subject to delisting unless it timely requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel" .
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), BIND: 0.40 (-0.01), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), CTIC: 0.43 (-0.01), IDRA: 1.50 (-0.07), CYCC: 5.95 (-0.14), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015
M2 - Thu Feb 04, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxbk98/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Aprogen, Inc. - Arno Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bellicum Pharmaceuticals, Inc. - Biogen, Inc. - BioInvent International AB - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Eli Lilly and Company - Emergent BioSolutions Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genor BioPharma Co., Ltd. - Gilead Sciences, Inc. - Grupo Ferrer Internacional, S.A. - Hospira, Inc. - Hutchison MediPharma Limited For more information visit http://www.researchandmarkets.com/research/fxbk98/chronic
EBS: 42.30 (-1.19), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), CTIC: 0.43 (-0.01), BMY: 72.65 (-0.08), CHRS: 16.01 (-0.94), CYCC: 5.95 (-0.14), BLCM: 12.91 (-0.03), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.65 (-0.05), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), LLY: 73.95 (-0.48), ATRA: 19.53 (-0.57), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), ATNM: 1.82 (unch), CYCC: 5.95 (-0.14), BLCM: 12.91 (-0.03), BPTH: 2.43 (-0.01), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), BXLT: 46.02 (-0.18), CBMG: 15.16 (+0.22)
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 18 Annual BIO CEO & Investor Conference on February 8 at 10:30 a.m. EST at the Waldorf Astoria in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.67 (-0.16), GSK: 40.93 (-1.13), MEIP: 1.39 (-0.02), AAAP: 31.26 (-0.67), MACK: 6.32 (-0.24), PGNX: 4.64 (-0.04), BLCM: 12.91 (-0.03), CYCC: 5.95 (-0.14), RXDX: 5.79 (-0.22), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), CBLI: 2.61 (+0.01), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.88 (-0.14), VRTX: 91.49 (-1.00), PFE: 35.29 (-0.02), GSK: 40.93 (-1.13), CNCE: 12.46 (-0.50), GLPG: 55.29 (-1.59), CYCC: 5.95 (-0.14), PTI: 20.10 (+0.84), SHPG: 177.10 (-6.85), PULM: 2.31 (-0.01), MRK: 56.81 (-0.37), NVLS: 4.41 (-0.03), PTCT: 7.24 (-0.30), KMDA: 3.75 (+0.04), AKTX: 15.00 (-0.41), NVS: 78.94 (-1.57)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.88 (-0.14), CYCC: 5.95 (-0.14), HZNP: 17.88 (-0.65), KMDA: 3.75 (+0.04), GSK: 40.93 (-1.13), AKTX: 15.00 (-0.41), APHB: 1.68 (-0.07), CNCE: 12.46 (-0.50), GLPG: 55.29 (-1.59)
BUYINS.NET: DSX, FFIC, PBS, XHB, CYCCP, DK Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Jan 25, 6:34AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Diana Shipping Inc (NYSE
SX), Flushing Financial Corp (NASDAQ:FFIC), Powershares Dynamic Media Portfolio (NYSE
BS), Spdr S&P Homebuilders Etf (NYSE:XHB), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP), Delek US Holdings Inc (NYSE K) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
PBS: 24.80 (-0.44), DSX: 2.37 (-0.20), CYCC: 5.95 (-0.14), XHB: 33.70 (-0.72), CYCCP: 6.97 (-0.03), FFIC: 20.78 (-0.22), DK: 13.39 (-0.11)
Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Dec 14, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company" , today announced the presentation of preclinical data demonstrating the molecular basis for the development of CYC065 in triple negative breast cancer (TNBC), and in particular basal-like TNBC. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2/9 dependent tumors. The data were presented at the San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2015.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Pharma (CYCC) Stock Skyrockets 50% on Positive Phase 1 Data
Madeleine Johnson - Zacks Investment Research - Mon Jun 06, 3:13PM CDT
On Monday, shares of Cyclacel Pharmaceuticals (CYCC) are skyrocketing, up over 50% after the company reported positive Phase 1 data for one of its lead drug candidates.
CYCC: 5.95 (-0.14)
Top Trending Stocks to Consider On Monday, June 6
ACCESSWIRE - Mon Jun 06, 1:01PM CDT
MIAMI, FL / ACCESSWIRE / June 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. Helios and Matheson Analytics Inc. (HMNY), LifeClips Inc. (LCLP), Cyclacel Pharmaceuticals, Inc. (CYCC) and Vascular Biogenics Ltd. (VBLT) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at DailyStockReporter.com.
CYCC: 5.95 (-0.14), VBLT: 4.90 (+0.10), HMNY: 9.29 (-1.81)
Cyclacel Reports Updated Data From Its DNA Damage Response Program on Seliciclib and Sapacitabine Combination in Patients With Solid Tumors at ASCO
GlobeNewswire - Mon Jun 06, 9:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), reported today updated Phase 1 data from its DNA damage response program evaluating a combination regimen of two Cyclacel product candidates, seliciclib, a cyclin dependent kinase (CDK) inhibitor, and sapacitabine, a nucleoside analogue. The regimen was orally-administered as sequential (Part 1) or concomitant (Part 2) treatment to 67 heavily-pretreated patients with advanced solid tumors. Antitumor activity was demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with a 35.6% disease control rate (1 CR, 5 PR and 10 SD). Treatment durations in responders ranged between 16 and over 240 weeks. No CR or PR was observed in BRCA negative patients. Data were presented at an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Reverse Stock Split
GlobeNewswire - Fri May 27, 4:00PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that effective at 5:00 p.m., Eastern Time, on May 27, 2016 (the "Effective Time" , the Company will effect a one-for-twelve reverse stock split of its outstanding common stock. The reverse stock split, which was unanimously approved by the Company's Board of Directors, was approved by its stockholders at the Annual Meeting of Stockholders held on May 26, 2016. The Company's common stock will open for trading on The NASDAQ Capital Market on May 31, 2016 on a post-split basis. CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel's Seliciclib-Sapacitabine Abstract Selected for Oral Presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire - Thu May 19, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the publication of an abstract selected for an oral presentation on Phase 1 data of an orally administered, combination regimen of seliciclib and sapacitabine in 67 patients with advanced solid tumors at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Pharmaceuticals Reports First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today reported its financial results and business highlights for the first quarter ended March 31, 2016. CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Pharmaceuticals to Release First Quarter 2016 Financial Results
GlobeNewswire - Wed May 04, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, will announce first quarter 2016 financial results on Wednesday, May 11, 2016. The Company will host a conference call and live webcast at 4:30 p.m. EDT on the same day. CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, is an Effective Inducer of Cell Death in B-cell Lymphoma and Synergizes With Bcl-2 or BET Inhibitors
GlobeNewswire - Mon Apr 18, 8:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) (Cyclacel or the Company), today announced the presentation of preclinical data demonstrating therapeutic potential of CYC065, the Company's second-generation, cyclin-dependent kinase (CDK) 2/9 inhibitor, as a targeted anti-cancer agent. The data show that CYC065 can induce cell death and combined beneficially with anti-cancer drugs from the Bcl-2 and BET inhibitor classes, in in vitro models of B-cell lymphoma, including double-hit lymphomas. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, April 16 - 20, 2016, in New Orleans.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Receipt of Nasdaq Extension
GlobeNewswire - Mon Apr 11, 6:00AM CDT
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), (NASDAQ:CYCCP); ("Cyclacel" or the "Company"
a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company received a written ruling from the NASDAQ Hearings Panel (the "Panel" stating that the Panel has granted the Company's request to remain listed on The NASDAQ Capital Market. CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Cyclacel Announces Receipt of Nasdaq Staff Determination; Company to Request Hearing
GlobeNewswire - Fri Feb 05, 3:20PM CST
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"
today announced that on February 2, 2016, the Company received a letter from the Listing Qualifications Staff (the "Staff" of The NASDAQ Stock Market LLC ("NASDAQ" indicating that the Company had not regained compliance with the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule 5450(a)(1), by the end of the previously granted compliance period that expired on February 2, 2016. As a result, the Staff indicated that the Company would be subject to delisting unless it timely requests a hearing before a NASDAQ Listing Qualifications Panel (the "Panel" . CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
Diffuse Large B-Cell Lymphoma Therapeutics Pipeline Review, H2 2015
M2 - Fri Feb 05, 4:18AM CST
Research and Markets (http://www.researchandmarkets.com/research/kwgllc/diffuse_large) has announced the addition of the "Diffuse Large B-Cell Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Diffuse Large B-Cell Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Diffuse Large B-Cell Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Diffuse Large B-Cell Lymphoma Overview - Therapeutics Development - Pipeline Products for Diffuse Large B-Cell Lymphoma - Overview - Pipeline Products for Diffuse Large B-Cell Lymphoma - Comparative Analysis - Diffuse Large B-Cell Lymphoma - Therapeutics under Development by Companies - Diffuse Large B-Cell Lymphoma - Therapeutics under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Diffuse Large B-Cell Lymphoma - Products under Development by Companies - Diffuse Large B-Cell Lymphoma - Products under Investigation by Universities/Institutes - Diffuse Large B-Cell Lymphoma - Companies Involved in Therapeutics Development - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Affimed Therapeutics AG - Amgen Inc. - Aprogen, Inc. - Arrien Pharmaceuticals, LLC - Astellas Pharma Inc. - AstraZeneca Plc - Aurigene Discovery Technologies Limited - Bayer AG - BeiGene(Beijing) Co.,Ltd - BIND Therapeutics, Inc. - Biocon Limited - Bristol-Myers Squibb Company - Celgene Corporation - Cell>Point, L.L.C. - Cellular Biomedicine Group, Inc. - Constellation Pharmaceuticals, Inc. - CTI BioPharma Corp. - Curis, Inc. - Cyclacel Pharmaceuticals, Inc. - Eisai Co., Ltd. - EpiZyme, Inc. - Erytech Pharma SA - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Gilead Sciences, Inc. - GlaxoSmithKline Plc - Hutchison MediPharma Limited - Idera Pharmaceuticals, Inc. - ImmunoGen, Inc. - Immunomedics, Inc. - Immunovaccine, Inc. - Incyte Corporation - Inflection Biosciences Limited For more information visit http://www.researchandmarkets.com/research/kw...fuse_large
CRIS: 1.69 (-0.10), IMMU: 3.05 (-0.08), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), BIND: 0.40 (-0.01), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), CTIC: 0.43 (-0.01), IDRA: 1.50 (-0.07), CYCC: 5.95 (-0.14), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Chronic Lymphocytic Leukemia (CLL) Pipeline Review, H2 2015
M2 - Thu Feb 04, 9:59AM CST
Research and Markets (http://www.researchandmarkets.com/research/fxbk98/chronic) has announced the addition of the "Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development (Partial List) - 4SC AG - AbbVie Inc. - Acetylon Pharmaceuticals, Inc. - Altor BioScience Corporation - Amgen Inc. - Aprogen, Inc. - Arno Therapeutics, Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Bayer AG - BeiGene(Beijing) Co.,Ltd - Bellicum Pharmaceuticals, Inc. - Biogen, Inc. - BioInvent International AB - Bionovis SA - Biothera, Inc. - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Coherus BioSciences, Inc. - CTI BioPharma Corp. - Cyclacel Pharmaceuticals, Inc. - Eli Lilly and Company - Emergent BioSolutions Inc. - Epirus Biopharmaceuticals, Inc. - F. Hoffmann-La Roche Ltd. - Genentech, Inc. - Genor BioPharma Co., Ltd. - Gilead Sciences, Inc. - Grupo Ferrer Internacional, S.A. - Hospira, Inc. - Hutchison MediPharma Limited For more information visit http://www.researchandmarkets.com/research/fxbk98/chronic
EBS: 42.30 (-1.19), AMGN: 154.78 (-2.00), LLY: 73.95 (-0.48), CTIC: 0.43 (-0.01), BMY: 72.65 (-0.08), CHRS: 16.01 (-0.94), CYCC: 5.95 (-0.14), BLCM: 12.91 (-0.03), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), ABBV: 61.00 (+0.25), CBMG: 15.16 (+0.22), CELGZ: 1.46 (-0.04)
Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/trfcb9/acute_lymphocytic) has announced the addition of the "Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview - Therapeutics Development - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Overview - Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Comparative Analysis - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Therapeutics under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Development by Companies - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Products under Investigation by Universities/Institutes - Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Companies Involved in Therapeutics Development Companies Mentioned - Partial List - 4SC AG - AbbVie Inc. - Actinium Pharmaceuticals, Inc. - Affimed Therapeutics AG - Altor BioScience Corporation - Amgen Inc. - Atara Biotherapeutics, Inc. - Baxalta Incorporated - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - Bio-Path Holdings, Inc. - BioSight Ltd. - Bristol-Myers Squibb Company - Calithera Biosciences, Inc. - Cantargia AB - Celator Pharmaceuticals, Inc. - Cellectis S.A. - Cellular Biomedicine Group, Inc. - Ceronco Biosciences - Constellation Pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - Daiichi Sankyo Company, Limited - DiNonA Inc. - Effimune SAS - Eli Lilly and Company - Epirus Biopharmaceuticals, Inc. - EpiZyme, Inc. - Erytech Pharma SA - Eureka Therapeutics, Inc. - Fate Therapeutics, Inc. - Formula Pharmaceuticals, Inc. - Gamida Cell Ltd. - GlaxoSmithKline Plc - Hangzhou Minsheng Pharmaceutical Group Co.,Ltd For more information visit http://www.researchandmarkets.com/research/tr...ymphocytic
FATE: 1.65 (-0.05), AMGN: 154.78 (-2.00), EPZM: 11.86 (-0.40), LLY: 73.95 (-0.48), ATRA: 19.53 (-0.57), GSK: 40.93 (-1.13), BMY: 72.65 (-0.08), ATNM: 1.82 (unch), CYCC: 5.95 (-0.14), BLCM: 12.91 (-0.03), BPTH: 2.43 (-0.01), CALA: 4.80 (-0.25), ABBV: 61.00 (+0.25), BXLT: 46.02 (-0.18), CBMG: 15.16 (+0.22)
Cyclacel Pharmaceuticals to Present at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Tue Feb 02, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) (Cyclacel or the Company), a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that the Company will present at the 18 Annual BIO CEO & Investor Conference on February 8 at 10:30 a.m. EST at the Waldorf Astoria in New York City. Spiro Rombotis, President and Chief Executive Officer, will provide an overview of the Company and its progress in key programs.
CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
Neuroblastoma - Pipeline Review, H2 2015
M2 - Thu Jan 28, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/lzkrbt/neuroblastoma) has announced the addition of the "Neuroblastoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Neuroblastoma Overview - Therapeutics Development - Pipeline Products for Neuroblastoma - Overview - Pipeline Products for Neuroblastoma - Comparative Analysis - Neuroblastoma - Therapeutics under Development by Companies - Neuroblastoma - Therapeutics under Investigation by Universities/Institutes - Neuroblastoma - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Neuroblastoma - Products under Development by Companies - Neuroblastoma - Products under Investigation by Universities/Institutes - Neuroblastoma - Companies Involved in Therapeutics Development - Ability Pharma, SL - Acetylon Pharmaceuticals, Inc. - Advanced Accelerator Applications SA - Ampio Pharmaceuticals, Inc. - APEIRON Biologics AG - AstraZeneca Plc - ATLAB Pharma SAS - Bellicum Pharmaceuticals, Inc. - Bexion Pharmaceuticals, LLC. - BioLineRx, Ltd. - Bionucleon Srl - Biotec Pharmacon ASA - Cebiotex, S.L. - Celgene Corporation - Chugai Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - CureFAKtor Pharmaceuticals, LLC - Cyclacel Pharmaceuticals, Inc. - DEKK-TEC, Inc. - Errant Gene Therapeutics, LLC - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline Plc - Ignyta, Inc. - Juno Therapeutics Inc. - Lindis Biotech GmbH - MabVax Therapeutics Holdings, Inc. - MEI Pharma, Inc. - Merck & Co., Inc. - Merrimack Pharmaceuticals, Inc. - Novartis AG - Novogen Limited - Pharmacyclics, Inc. - Pono Pharma - Progenics Pharmaceuticals, Inc. - Recombio S.L For more information visit http://www.researchandmarkets.com/research/lz...roblastoma
PCYC: 261.25 (+1.70), AMPE: 3.67 (-0.16), GSK: 40.93 (-1.13), MEIP: 1.39 (-0.02), AAAP: 31.26 (-0.67), MACK: 6.32 (-0.24), PGNX: 4.64 (-0.04), BLCM: 12.91 (-0.03), CYCC: 5.95 (-0.14), RXDX: 5.79 (-0.22), MRK: 56.81 (-0.37), AZN: 27.97 (-0.99), JUNO: 42.98 (-2.55), CBLI: 2.61 (+0.01), NVS: 78.94 (-1.57), CELGZ: 1.46 (-0.04)
Cystic Fibrosis Pipeline H2 2015 Report on Drugs and Companies
PR Newswire - Thu Jan 28, 12:00AM CST
New market research titled "Cystic Fibrosis - Pipeline Review, H2 2015" is now available with ReportsnReports.com and provides an overview of the Cystic Fibrosis's therapeutic pipeline to help strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
INSM: 10.88 (-0.14), VRTX: 91.49 (-1.00), PFE: 35.29 (-0.02), GSK: 40.93 (-1.13), CNCE: 12.46 (-0.50), GLPG: 55.29 (-1.59), CYCC: 5.95 (-0.14), PTI: 20.10 (+0.84), SHPG: 177.10 (-6.85), PULM: 2.31 (-0.01), MRK: 56.81 (-0.37), NVLS: 4.41 (-0.03), PTCT: 7.24 (-0.30), KMDA: 3.75 (+0.04), AKTX: 15.00 (-0.41), NVS: 78.94 (-1.57)
Cystic Fibrosis - Pipeline Review, H2 2015
M2 - Wed Jan 27, 8:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/llcrjt/cystic_fibrosis) has announced the addition of the "Cystic Fibrosis - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Cystic Fibrosis. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Reasons to buy: - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cystic Fibrosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cystic Fibrosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actelion Ltd - Akari Therapeutics, Plc - Alaxia SAS - AlgiPharma AS - AmpliPhi Biosciences Corporation - Arcturus Therapeutics, Inc - Aridis Pharmaceuticals LLC - Bayer AG - Boehringer Ingelheim GmbH - Carolus Therapeutics, Inc. - Celtaxsys, Inc. - Chiesi Farmaceutici SpA - Cilian AG - Concert Pharmaceuticals, Inc. - Corbus pharmaceuticals, Inc. - Cyclacel Pharmaceuticals, Inc. - DiscoveryBiomed, Inc. - Errant Gene Therapeutics, LLC - Galapagos NV - GlaxoSmithKline Plc - Grifols, S.A. - Grupo Praxis Pharmaceutical SA - Horizon Pharma Plc - Insmed Incorporated - Invion Limited - JHL Biotech, Inc. - Kamada Ltd. - La Jolla Pharmaceutical Company - Lamellar Biomedical Ltd - Laurent Pharmaceuticals Inc. - (30 Others) For more information visit http://www.researchandmarkets.com/research/ll...c_fibrosis
INSM: 10.88 (-0.14), CYCC: 5.95 (-0.14), HZNP: 17.88 (-0.65), KMDA: 3.75 (+0.04), GSK: 40.93 (-1.13), AKTX: 15.00 (-0.41), APHB: 1.68 (-0.07), CNCE: 12.46 (-0.50), GLPG: 55.29 (-1.59)
BUYINS.NET: DSX, FFIC, PBS, XHB, CYCCP, DK Are Seasonally Ripe To Go Up In the Next Five Weeks
M2 - Mon Jan 25, 6:34AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Diana Shipping Inc (NYSE
SX), Flushing Financial Corp (NASDAQ:FFIC), Powershares Dynamic Media Portfolio (NYSE BS), Spdr S&P Homebuilders Etf (NYSE:XHB), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCCP), Delek US Holdings Inc (NYSE K) and each have a high seasonal probability to go Up in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: PBS: 24.80 (-0.44), DSX: 2.37 (-0.20), CYCC: 5.95 (-0.14), XHB: 33.70 (-0.72), CYCCP: 6.97 (-0.03), FFIC: 20.78 (-0.22), DK: 13.39 (-0.11)
Molecular Basis for Development of Cyclacel's CYC065 CDK2/9 Inhibitor in Triple-Negative Breast Cancer Presented at San Antonio Breast Cancer Symposium
GlobeNewswire - Mon Dec 14, 6:00AM CST
Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company"
, today announced the presentation of preclinical data demonstrating the molecular basis for the development of CYC065 in triple negative breast cancer (TNBC), and in particular basal-like TNBC. CYC065 is a highly-selective, second-generation cyclin dependent kinase (CDK) inhibitor targeting CDK2/9 dependent tumors. The data were presented at the San Antonio Breast Cancer Symposium (SABCS), taking place December 8-12, 2015. CYCC: 5.95 (-0.14), CYCCP: 6.97 (-0.03)
